Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Equivalents (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Cash & Equivalents data on record, last reported at $90.4 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 10.69% year-over-year to $90.4 million; the TTM value through Dec 2025 reached $90.4 million, down 10.69%, while the annual FY2025 figure was $90.4 million, 10.69% down from the prior year.
  • Cash & Equivalents reached $90.4 million in Q4 2025 per TRDA's latest filing, down from $93.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $227.6 million in Q1 2023 and bottomed at $45.2 million in Q4 2022.
  • Average Cash & Equivalents over 4 years is $91.1 million, with a median of $78.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 168.96% in 2023, then plummeted 69.94% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $45.2 million in 2022, then surged by 49.7% to $67.6 million in 2023, then surged by 49.72% to $101.2 million in 2024, then dropped by 10.69% to $90.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $90.4 million in Q4 2025, $93.3 million in Q3 2025, and $72.5 million in Q2 2025.